🇺🇸 simvastatin and ezetimibe in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Drug Interaction — 2 reports (18.18%)
2. Muscular Weakness — 1 report (9.09%)
3. Myalgia — 1 report (9.09%)
4. Myopathy — 1 report (9.09%)
5. Myositis — 1 report (9.09%)
6. Pain In Extremity — 1 report (9.09%)
7. Quadriparesis — 1 report (9.09%)
8. Respiratory Failure — 1 report (9.09%)
9. Rhabdomyolysis — 1 report (9.09%)
10. Spinal Column Stenosis — 1 report (9.09%)

Source database →

Frequently asked questions

Is simvastatin and ezetimibe approved in United States?

simvastatin and ezetimibe does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for simvastatin and ezetimibe in United States?

UMC Utrecht is the originator. The local marketing authorisation holder may differ — check the official source linked above.